William Blair & Company
GILD icon

William Blair & Company’s Gilead Sciences GILD Stock Holding History

William Blair & Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,200
Closed -$156K – 1420
2017
Q2 		$156K Sell
2,200
-200
-8% -$13.3K ﹤0.01% 1386
2017
Q1 		$163K Buy
+2,400
New +$169K ﹤0.01% 1249

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

William Blair & Company's GILD Position: Q1 2026 in Review

William Blair & Company reduced its Gilead Sciences (GILD) stake by 7.7% in Q1 2026, selling an estimated $4M and leaving 340,345 shares worth $47.4M. The position accounts for 0.14% of the portfolio, ranked #146.

William Blair & Company first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $517M in Q3 2014. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • William Blair & Company held 340,345 shares of Gilead Sciences worth $47.4M as of Q1 2026.
  • William Blair & Company sold 28,585 Gilead Sciences shares in Q1 2026, an estimated $4M.
  • Gilead Sciences made up 0.14% of William Blair & Company's portfolio in Q1 2026, its #146 holding.
  • William Blair & Company first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • William Blair & Company's Gilead Sciences position peaked at $517M in Q3 2014.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.